Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $78.81 and last traded at $76.77, with a volume of 186738 shares changing hands. The stock had previously closed at $71.95.
Key Stories Impacting Nektar Therapeutics
Here are the key news stories impacting Nektar Therapeutics this week:
- Neutral Sentiment: Rosen Law Firm and other firms are issuing routine notices reminding purchasers of NKTR securities of the May 5, 2026 lead‑plaintiff deadline — this is a procedural development that increases publicity around the litigation but does not itself determine outcome or damages. ROSEN, A LEADING NATIONAL FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – NKTR
- Negative Sentiment: Levi & Korsinsky’s investor alert highlights allegations that Nektar made misrepresentations about REZOLVE‑AA patient enrollment compliance and invites investors to seek lead‑plaintiff status, intensifying claims that could lead to damages or settlements. NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky
- Negative Sentiment: Pomerantz LLP (and multiple other firms including Bernstein Liebhard, Glancy Prongay Wolke & Rotter, Schall, Faruqi & Faruqi, Bronstein Gewirtz & Grossman, Robbins, and The Gross Law Firm) either filed or announced investigations/class actions against Nektar covering purchases between Feb 26, 2025 and Dec 15, 2025 — the breadth of filings raises the probability of consolidated litigation and potential settlement exposure. Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
- Negative Sentiment: Multiple press releases from plaintiff firms (e.g., Glancy, Bernstein, Rosen, Schall) are actively soliciting lead plaintiffs — increased publicity can accelerate selling pressure and volatility as investors price in legal risk and uncertainty around regulatory scrutiny and clinical program impacts. Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Wall Street Analyst Weigh In
Several equities analysts have commented on NKTR shares. Piper Sandler reiterated an “overweight” rating and issued a $105.00 price objective on shares of Nektar Therapeutics in a report on Monday, January 26th. William Blair raised shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 10th. Wall Street Zen lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. Wedbush initiated coverage on shares of Nektar Therapeutics in a report on Tuesday, March 24th. They issued a “neutral” rating and a $70.00 price target on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Nektar Therapeutics in a research report on Monday, December 29th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $128.13.
Nektar Therapeutics Stock Performance
The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of -7.48 and a beta of 1.17. The business has a fifty day simple moving average of $61.37 and a 200 day simple moving average of $56.25.
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last posted its earnings results on Thursday, March 12th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.69) by $0.91. The company had revenue of $21.81 million during the quarter, compared to the consensus estimate of $10.44 million. Nektar Therapeutics had a negative return on equity of 386.16% and a negative net margin of 297.07%. On average, sell-side analysts forecast that Nektar Therapeutics will post -0.72 earnings per share for the current fiscal year.
Insider Activity
In other Nektar Therapeutics news, CEO Howard W. Robin sold 423 shares of Nektar Therapeutics stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $73.00, for a total value of $30,879.00. Following the completion of the sale, the chief executive officer owned 75,489 shares in the company, valued at $5,510,697. The trade was a 0.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jonathan Zalevsky sold 3,867 shares of the business’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $35.67, for a total transaction of $137,935.89. Following the completion of the sale, the insider directly owned 21,354 shares of the company’s stock, valued at $761,697.18. This represents a 15.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 4,470 shares of company stock valued at $181,955 in the last quarter. Corporate insiders own 3.71% of the company’s stock.
Institutional Investors Weigh In On Nektar Therapeutics
Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets increased its stake in Nektar Therapeutics by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 210 shares during the period. Headlands Technologies LLC acquired a new position in Nektar Therapeutics in the 2nd quarter valued at $65,000. Integrated Wealth Concepts LLC bought a new stake in shares of Nektar Therapeutics during the 1st quarter valued at $68,000. Quarry LP bought a new stake in shares of Nektar Therapeutics during the 4th quarter valued at $85,000. Finally, Compass Wealth Management LLC acquired a new stake in shares of Nektar Therapeutics during the 3rd quarter worth $88,000. Institutional investors and hedge funds own 75.88% of the company’s stock.
About Nektar Therapeutics
Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.
Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.
See Also
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
